Skip to main content



Review of National Medicines Policy - Allergy and Anaphylaxis Australia submission - 8 Oct 2021

Allergy & Anaphylaxis Australia (A&AA) lodged a submission to the Review of National Medicines Policy. 

Included were submisions on:

Terms of Reference 1: Evaluate the current NMP objectives and determine whether these should be modified or additional objectives included. This includes consideration of the proposed Principles to be included within the NMP.

Terms of Reference 2: Consider the definition of medicines and whether the NMP needs to be expanded to include health technologies.

Terms of Reference 3. Assess the NMP’s utility in the context of rapidly evolving treatment options, population changes, interconnected relationships, and system-wide capacities.

Terms of Reference 4: Consider the centricity of the consumer within the NMP and whether it captures the diversity of consumers’ needs and expectations.

Terms of Reference 5: Identify options to improve the NMP’s governance; communications, implementation (including enablers) and evaluation.

Terms of Reference 6: Review the NMP partners and provide options for building greater accountability including addressing conflicts of interest

pdfReview of National Medicines Policy AAA Submission. 8 October 2021265.25 KB



If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.